Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Quoin Pharmaceuticals Ltd ADR (QNRX)

Quoin Pharmaceuticals Ltd ADR (QNRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study GlobeNewswire - Mon Jan 6, 7:30AM CST

QNRX : 0.6700 (-4.33%)
Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering GlobeNewswire - Fri Dec 20, 2024

QNRX : 0.6700 (-4.33%)
Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study GlobeNewswire - Thu Dec 19, 2024

QNRX : 0.6700 (-4.33%)
Quoin Pharmaceuticals Reports Positive Interim Clinical Data for QRX003 in Netherton Syndrome Studies Quiver Quantitative, Inc. - Wed Dec 18, 2024

Quoin Pharmaceuticals reports positive interim results for QRX003 in Netherton Syndrome studies, showing significant skin improvement without safety concerns.Quiver AI SummaryQuoin Pharmaceuticals Ltd....

QNRX : 0.6700 (-4.33%)
Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies GlobeNewswire - Wed Dec 18, 2024

QNRX : 0.6700 (-4.33%)
Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results GlobeNewswire - Thu Nov 7, 2024

QNRX : 0.6700 (-4.33%)
Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient GlobeNewswire - Tue Nov 5, 2024

QNRX : 0.6700 (-4.33%)
Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024 GlobeNewswire - Thu Oct 31, 2024

QNRX : 0.6700 (-4.33%)
Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome GlobeNewswire - Tue Oct 22, 2024

QNRX : 0.6700 (-4.33%)
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics ACN Newswire - Thu Aug 17, 2023

Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics

QNRX : 0.6700 (-4.33%)
ASXC : 0.3479 (+0.64%)

Barchart Exclusives

2 ‘Strong Buy’-Rated Energy Stocks to Buy for Fat Yields in 2025 Barchart - 1 hour ago
These high-yield dividend stocks have maintained payouts even during periods of market turbulence. Further, they sport “Strong Buy” ratings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot